CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Efficacy and safety of once-weekly dulaglutide versus insulin glargine, both with prandial insulin lispro (+/- metformin), in an AWARD-4 subpopulation of patients with type 2 diabetes (T2D) and baseline HbA1c (≥7.5% and ≤11%) above the Ger…
DOI 10.1055/s-0035-1549548
Bibliografische Angaben
Nachweis in CareLit
Autor:innenE Heitmann, C Nicolay, H Jung, M Füchtenbusch
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: German national treatment guidelines recommend HbA1c target range 6.5 – 7.5% for 'healthy' patients with T2D. Data from an open-label AWARD-4 subpopulation with baseline HbA1c ≥7.5% (above recommended target range) and ≤11% (˜80% intent-to-treat population) were analysed comparing dulaglutide vs. glargine, both with lispro ± metformin. Methods: Efficacy and safety data from eligible patients uncontrolled…
Zitieren
Zitierempfehlung
E Heitmann, C Nicolay, H Jung, M Füchtenbusch (2015) Efficacy and safety of once-weekly dulaglutide versus insulin glargine, both with prandial insulin lispro (+/- metformin), in an AWARD-4 subpopulation of patients with type 2 diabetes (T2D) and baseline HbA1c (≥7.5% and ≤11%) above the German recommended HbA1c treatment target range. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549548
Mit CareLit weiterarbeiten